ClinicalTrials.gg
RecruitingNCT07032298Updated Jul 25, 2025

A Phase I Study of SSGJ-612 in Patients With Advanced Solid Tumors

A Phase 1 interventional study of SSGJ-612 in Advanced Malignant Tumors, sponsored by Shenyang Sunshine Pharmaceutical Co., LTD.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-25.

Sponsored by Shenyang Sunshine Pharmaceutical Co., LTD. (part of 3SBio Inc.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is an open-label phase I study to evaluate the safety, pharmacokinetics, and antitumor activity of SSGJ-612 in patients with advanced malignant solid tumors expressing HER2.

Read the detailed description

The clinical trial consists of two phases. In the dose escalation stage, the accelerated titration method combined with the traditional "3+3" design will be adopted, to evaluate the safety and dose-limiting toxicity (DLT), and to determine the maximum tolerated dose (MTD) or the maximum dose of administration (MAD). In the dose expansion phase, several safe and effective dose levels of SSGJ-612 will be expanded and further evaluated in larger groups of participants.

02

Conditions studied

  • Advanced Malignant Tumors
03

In context

Lead sponsor

Shenyang Sunshine Pharmaceutical Co., LTD. is the lead sponsor of 40 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participate in this study, be willing to follow and complete all trial procedures, and sign the form;
  2. Aged ≥18 and ≤75 years old at the time of signing the ICF, regardless of gender;
  3. Expected survival ≥3 months;
  4. Performance status (PS) score of 0-1 according to the (ECOG) scale;
  5. Patients with or cytologically confirmed locally advanced or malignant tumors who have failed standard treatment, are intolerant to standard treatment, or have no standard treatment available, and cannot undergo complete surgical resection or receive radical concurrent/sequential chemoradiotherapy;
  6. Tumor tissue with expression;
  7. At least one measurable tumor lesion assessed as the target lesion according to v1.1 criteria, and the lesion is suitable for repeated and accurate measurement.

Exclusion criteria

Exclusion Criteria:

  1. Presence of brainstem, meninges, or spinal cord , or spinal cord compression;
  2. Presence of active central nervous system (CNS) metastatic lesions;
  3. Individuals with clinical symptoms or requiring repeated drainage (once a month or more frequently) of pleural effusion, pericardial effusion, or ascites;
  4. Primary or secondary immunodeficiency, including positive (HIV) test;
  5. Known active tuberculosis; known active syphilis infection;
  6. Known history of allogeneic organ transplantation or hematopoietic stem cell transplantation;
  7. Use of any or attenuated live vaccine within 4 weeks before the first dose, or plan to receive any live vaccine or attenuated live vaccine during the study;
  8. Known severe allergic history to any component of the drug, or history of severe allergic reaction to antibodies;
  9. Pregnant or lactating women.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    SSGJ-612

    In dose escalation phase, participants will receive one of the five increasing dose levels of SSGJ-612 respectively, intravenously (IV). During or after dose escalation, any dose levels that does not exceed the MTD can be expanded.

    Drug: SSGJ-612

Interventions

  • DrugSSGJ-612

    Intravenous injection

06

What researchers measure

Primary outcomes

  1. Incidence and severity of Adverse Events (AEs)

    Adverse Events (AEs) refers to all adverse medical events that occur in patients after they receive the investigational drug and do not necessarily have a causal relationship with the investigational drug. AEs were evaluated according to CTCAE V5.0.

    Time frame: Through study completion, an average of 1 year

  2. Incidence of DLT

    Dose-Limiting Toxicity

    Time frame: 14 days

Secondary outcomes

  1. ORR assessed by investigators per RECIST v1.1

    Objective Response Rate (ORR) is the proportion of patients with Complete Response (CR) or Partial Response (PR), assessed by investigators per RECIST v1.1.

    Time frame: Through study completion, an average of 1 year

  2. DoR assessed by investigators per RECIST v1.1

    Duration of Response (DoR) is the time between the first onset of CR or PR and the first onset of Disease Progression (PD) (assessed by investigators per RECIST v1.1) or death from any cause.

    Time frame: Through study completion, an average of 1 year

  3. DCR assessed by investigators per RECIST v1.1

    Disease Control Rate (DCR) is the proportion of patients with CR, PR, and Stable Disease (SD), assessed by investigators per RECIST v1.1.

    Time frame: Through study completion, an average of 1 year

  4. TTR assessed by investigators per RECIST v1.1

    Time to Response (TTR) is the time from the start of treatment until the date of first documented response (assessed by investigators per RECIST v1.1).

    Time frame: Through study completion, an average of 1 year

  5. PFS

    Progression-Free Survival (PFS) is the time between first initiation of study treatment to PD (assessed by investigators per RECIST v1.1) or death due to any reason.

    Time frame: Through study completion, an average of 1 year

  6. OS

    Overall Survival (OS) is defined as the time from the start of treatment with SSGJ-612 until death due to any cause.

    Time frame: Through study completion, an average of 1 year

  7. Cmax of SSGJ-612

    Peak concentration (Cmax), in single dose period and multiple dose periods.

    Time frame: Through study completion, an average of 1 year

  8. Cmin of SSGJ-612

    Trough concentration (Cmin), in multiple dose periods.

    Time frame: Through study completion, an average of 1 year

  9. Tmax of SSGJ-612

    Peak time (Tmax), in single dose period and multiple dose periods.

    Time frame: Through study completion, an average of 1 year

  10. T1/2 of SSGJ-612

    Elimination phase half-life (T1/2), in single dose period and multiple dose periods.

    Time frame: Through study completion, an average of 1 year

  11. AUC0-last

    Area under plasma concentration-time curve from 0 to the last quantifiable time point (AUC0-t), in single dose period and multiple dose periods.

    Time frame: Through study completion, an average of 1 year

  12. Incidence of ADA and Nab

    Number of patients with detectable Anti-drug Antibody (ADA) and Neutralizing Antibodies (NAb).

    Time frame: Through study completion, an average of 1 year

  13. The correlation between HER2 expression and efficacy

    The correlation between expression level of HER2 in tumor tissues and anti-tumor activity.

    Time frame: Through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Apr 2026, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2025
First posted
Jun 23, 2025
StartActual
Jul 18, 2025
Primary completionEst.
Apr 2026
CompletionEst.
Jun 2026
Last update
Jul 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07032298
Responsible party
Sponsor
First posted
Jun 23, 2025
Start date
Jul 18, 2025
Primary completion
Apr 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Jul 25, 2025

Study contacts

Jun Yao, M.D.
Contact
yaojun74@163.com
13663790098
Cai'e Wang, M.D.
Contact
2454544618@qq.com
13837915297

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion